Cyclical regulation of the insulin-like growth factor binding protein 3 gene in response to 1α,25-dihydroxyvitamin D3

The nuclear receptor vitamin D receptor (VDR) is known to associate with two vitamin D response element (VDRE) containing chromatin regions of the insulin-like growth factor binding protein 3 (IGFBP3) gene. In non-malignant MCF-10A human mammary cells, we show that the natural VDR ligand 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) causes cyclical IGFBP3 mRNA accumulation with a periodicity of 60 min, while in the presence of the potent VDR agonist Gemini the mRNA is continuously accumulated. Accordingly, VDR also showed cyclical ligand-dependent association with the chromatin regions of both VDREs. Histone deacetylases (HDACs) play an important role both in VDR signalling and in transcriptional cycling. From the 11 HDAC gene family members, only HDAC4 and HDAC6 are up-regulated in a cyclical fashion in response to 1α,25(OH)2D3, while even these two genes do not respond to Gemini. Interestingly, HDAC4 and HDAC6 proteins show cyclical VDR ligand-induced association with both VDRE regions of the IGFBP3 gene, which coincides with histone H4 deacetylation on these regions. Moreover, combined silencing of HDAC4 and HDAC6 abolishes the cycling of the IGFBP3 gene. We assume that due to more efficient VDR interaction, Gemini induces longer lasting chromatin activation and therefore no transcriptional cycling but monotonically increasing IGFBP3 mRNA. In conclusion, 1α,25(OH)2D3 regulates IGFBP3 transcription through short-term cyclical association of VDR, HDAC4 and HDAC6 to both VDRE-containing chromatin regions.

[1]  D. S. Broomhead,et al.  Pulsatile Stimulation Determines Timing and Specificity of NF-κB-Dependent Transcription , 2009, Science.

[2]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  Z. Gucev,et al.  Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. , 1996, The international journal of biochemistry & cell biology.

[4]  N. Pejnović,et al.  Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. , 1999, Clinical and experimental rheumatology.

[5]  J. Chen,et al.  The SRC family of nuclear receptor coactivators. , 2000, Gene.

[6]  P. Cohen,et al.  Rapid Apoptosis Induction by IGFBP-3 Involves an Insulin-like Growth Factor-independent Nucleomitochondrial Translocation of RXRα/Nur77* , 2005, Journal of Biological Chemistry.

[7]  M. Groudine,et al.  Controlling the double helix , 2003, Nature.

[8]  C. Carlberg,et al.  Regulation of multiple insulin-like growth factor binding protein genes by 1α,25-dihydroxyvitamin D3 , 2005, Nucleic acids research.

[9]  G. Pirianov,et al.  Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. , 1999, European journal of cancer.

[10]  P. Lips Vitamin D physiology. , 2006, Progress in biophysics and molecular biology.

[11]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[12]  C. Fullmer,et al.  Vitamin D and intestinal calcium transport: facts, speculations and hypotheses. , 1995, The Journal of nutrition.

[13]  P. Becker,et al.  Energy‐dependent chromatin accessibility and nucleosome mobility in a cell‐free system. , 1995, The EMBO journal.

[14]  Sungtae Kim,et al.  1,25‐Dihydroxyvitamin D3 Stimulates Cyclic Vitamin D Receptor/Retinoid X Receptor DNA‐Binding, Co‐activator Recruitment, and Histone Acetylation in Intact Osteoblasts , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[15]  B. Turner,et al.  An increasingly complex code. , 2002, The Journal of clinical investigation.

[16]  C. Carlberg The impact of transcriptional cycling on gene regulation , 2010, Transcription.

[17]  M. Uskoković,et al.  A 1α,25-Dihydroxyvitamin D3 Analog Enhances Regulatory T-Cells and Arrests Autoimmune Diabetes in NOD Mice , 2002 .

[18]  F. Dequiedt,et al.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. , 2002, Molecular cell.

[19]  R. Simpson,et al.  c-myc Intron Element-binding Proteins Are Required for 1,25-Dihydroxyvitamin D3 Regulation of c-myc during HL-60 Cell Differentiation and the Involvement of HOXB4* , 1999, The Journal of Biological Chemistry.

[20]  R. Baxter Insulin-like growth factor binding proteins in the human circulation: a review. , 1994, Hormone research.

[21]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[22]  A. Nohe,et al.  Molecular basis of the potential of vitamin D to prevent cancer , 2008, Current medical research and opinion.

[23]  J. Welsh,et al.  Vitamin D(3) receptor ablation alters mammary gland morphogenesis. , 2002, Development.

[24]  S. Nagpal,et al.  Noncalcemic actions of vitamin D receptor ligands. , 2005, Endocrine reviews.

[25]  Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. , 1999, Endocrinology.

[26]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[27]  K. Umesono,et al.  Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.

[28]  C. Mathieu,et al.  Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3 , 1994, Diabetologia.

[29]  C. Carlberg,et al.  Corepressor excess shifts the two-side chain vitamin D analog Gemini from an agonist to an inverse agonist of the vitamin D receptor. , 2003, Molecular endocrinology.

[30]  D. Steinhilber,et al.  Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. , 2007, Biochimica et biophysica acta.

[31]  J. Auwerx,et al.  Sirtuin functions in health and disease. , 2007, Molecular endocrinology.

[32]  J. Welsh Targets of Vitamin D Receptor Signaling in the Mammary Gland , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  R. Bouillon,et al.  Nonhypercalcemic vitamin D analogs: interactions with the vitamin D-binding protein. , 1996, Hormone research.

[34]  F. Dequiedt,et al.  Human HDAC7 Histone Deacetylase Activity Is Associated with HDAC3in Vivo * , 2001, The Journal of Biological Chemistry.

[35]  P. Yamada,et al.  Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. , 2009, American journal of physiology. Cell physiology.

[36]  E. Giovannucci,et al.  Vitamin D and prevention of breast cancer: Pooled analysis , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  B. Turner,et al.  Cellular Memory and the Histone Code , 2002, Cell.

[38]  Craig L. Peterson,et al.  Chromatin Higher Order Folding--Wrapping up Transcription , 2002, Science.

[39]  J. Welsh Vitamin D and prevention of breast cancer , 2007, Acta Pharmacologica Sinica.

[40]  P. Yin,et al.  Paradoxical Actions of Endogenous and Exogenous Insulin-like Growth Factor-binding Protein-5 Revealed by RNA Interference Analysis* , 2004, Journal of Biological Chemistry.

[41]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[42]  M. Lambert,et al.  Activation of nuclear receptors: a perspective from structural genomics. , 2003, Structure.

[43]  Elina Hyppönen,et al.  Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study , 2001, The Lancet.

[44]  T. Cotter,et al.  Histone deacetylase activity in conjunction with E2F‐1 and p53 regulates Apaf‐1 expression in 661W cells and the retina , 2009, Journal of neuroscience research.

[45]  C. Carlberg,et al.  Gene regulation by vitamin D3. , 1998, Critical reviews in eukaryotic gene expression.

[46]  R. Baxter,et al.  IGF-binding protein-3-induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. , 2002, Endocrinology.

[47]  T. Kouzarides,et al.  Regulation of E2F1 activity by acetylation , 2000, The EMBO journal.

[48]  R. Radulescu,et al.  Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. , 1997, Endocrinology.

[49]  Jose Russo,et al.  Human Breast Epithelial Cell Line, MCF-10 Isolation and Characterization of a Spontaneously Immortalized , 2006 .

[50]  A. Aranda,et al.  Synergistic activation of the prolactin promoter by vitamin D receptor and GHF-1: role of the coactivators, CREB-binding protein and steroid hormone receptor coactivator-1 (SRC-1). , 1999, Molecular endocrinology.

[51]  B. Hollis Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. , 2005, The Journal of nutrition.

[52]  C. Carlberg,et al.  Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. , 2006, Current topics in medicinal chemistry.

[53]  L. Freedman,et al.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.

[54]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[55]  C. Carlberg,et al.  Ligand-triggered stabilization of vitamin D receptor/retinoid X receptor heterodimer conformations on DR4-type response elements. , 2000, Journal of molecular biology.

[56]  C. Carlberg,et al.  Regulation of the human cyclin C gene via multiple vitamin D3-responsive regions in its promoter , 2005, Nucleic acids research.

[57]  C. Carlberg,et al.  VDR‐Alien: a novel, DNA‐selective vitamin D3 receptor‐corepressor partnership , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  V. Hwa,et al.  The Insulin-like Growth Factor-binding Protein (igfbp) Superfamily* , 2022 .

[59]  Neil J. McKenna,et al.  Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators , 2002, Cell.

[60]  A. Ascherio,et al.  Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. , 2006, JAMA.

[61]  C. Monneret,et al.  Histone deacetylase inhibitors. , 2005, European journal of medicinal chemistry.

[62]  C. Carlberg,et al.  New vitamin D receptor ligands , 2003 .

[63]  H. Huynh,et al.  Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. , 1999, The Journal of endocrinology.

[64]  H. DeLuca Overview of general physiologic features and functions of vitamin D. , 2004, The American journal of clinical nutrition.

[65]  C. Tepper,et al.  1,25-Dihydroxyvitamin D3 protects HL60 cells against apoptosis but down-regulates the expression of the bcl-2 gene. , 1993, Experimental cell research.

[66]  C. Carlberg,et al.  Vitamin D Receptor Agonists Specifically Modulate the Volume of the Ligand-binding Pocket* , 2006, Journal of Biological Chemistry.

[67]  C. Carlberg Ligand-mediated conformational changes of the VDR are required for gene transactivation , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[68]  G. Martino,et al.  Inhibition of Th1 development and treatment of chronic‐relapsing experimental allergic encephalomyelitis by a non‐hypercalcemic analogue of 1,25‐dihydroxyvitamin D3 , 2000, European journal of immunology.

[69]  Heike Brand,et al.  Estrogen Receptor-α Directs Ordered, Cyclical, and Combinatorial Recruitment of Cofactors on a Natural Target Promoter , 2003, Cell.

[70]  C. Perks,et al.  Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. , 1998, Journal of molecular endocrinology.

[71]  R. Bouillon,et al.  Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells , 1998, Molecular and Cellular Endocrinology.

[72]  M. Grunstein Histone acetylation in chromatin structure and transcription , 1997, Nature.

[73]  C. Carlberg,et al.  Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. , 2001, The Journal of investigative dermatology.

[74]  J. Clifford,et al.  Direct Functional Interactions between Insulin-like Growth Factor-binding Protein-3 and Retinoid X Receptor-α Regulate Transcriptional Signaling and Apoptosis* , 2000, The Journal of Biological Chemistry.

[75]  T. Shinki,et al.  Vitamin D and bone , 2003, Journal of cellular biochemistry.

[76]  P. Becker Nucleosome sliding: facts and fiction , 2002, The EMBO journal.

[77]  H. Pols,et al.  Conformational change and enhanced stabilization of the vitamin D receptor by the 1,25-dihydroxyvitamin D3 analog KH1060. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Welsh,et al.  Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. , 2004, Molecular endocrinology.

[79]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[80]  Anna Saramäki,et al.  Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to trichostatin A and 1α,25-dihydroxyvitamin D3 , 2007, Nucleic acids research.

[81]  R. Baxter,et al.  Insulin-like Growth Factor-binding Protein (IGFBP)-3 and IGFBP-5 Share a Common Nuclear Transport Pathway in T47D Human Breast Carcinoma Cells* , 1998, The Journal of Biological Chemistry.

[82]  Vincent Laudet,et al.  International Union of Pharmacology. LXVI. Orphan Nuclear Receptors , 2006, Pharmacological Reviews.

[83]  D. Leroith,et al.  Membrane-associated Insulin-like Growth Factor-binding Protein-3 Inhibits Insulin-like Growth Factor-I-induced Insulin-like Growth Factor-I Receptor Signaling in Ishikawa Endometrial Cancer Cells* , 1997, The Journal of Biological Chemistry.

[84]  C. Carlberg,et al.  Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists. , 2000, Molecular pharmacology.

[85]  Yong Ming Li,et al.  Regulation of Myeloid Growth and Differentiation by the Insulin-Like Growth Factor I Receptor1. , 1997, Endocrinology.

[86]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[87]  A. Howell,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. , 2006, Endocrine-related cancer.

[88]  S. Grewal,et al.  Heterochromatin: silence is golden , 2003, Current Biology.

[89]  C. Mathieu,et al.  Non-hypercalcemic pharmacological aspects of vitamin D analogs. , 1995, Biochemical pharmacology.

[90]  C. Carlberg,et al.  Structural evaluation of the agonistic action of a vitamin D analog with two side chains binding to the nuclear vitamin D receptor. , 2003, Molecular pharmacology.

[91]  Anna Saramäki,et al.  Controlling the chromatin organization of vitamin D target genes by multiple vitamin D receptor binding sites , 2007, The Journal of Steroid Biochemistry and Molecular Biology.

[92]  C. Mathieu,et al.  Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. , 1995, Endocrinology.

[93]  M. Pollak,et al.  Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. , 1999, International journal of oncology.

[94]  S. Leal,et al.  The Type V Transforming Growth Factor β Receptor Is the Putative Insulin-like Growth Factor-binding Protein 3 Receptor* , 1997, The Journal of Biological Chemistry.

[95]  Nick Gilbert,et al.  Chromatin Architecture of the Human Genome Gene-Rich Domains Are Enriched in Open Chromatin Fibers , 2004, Cell.

[96]  C. Carlberg,et al.  Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene. , 2009, Journal of molecular biology.

[97]  M. Webber,et al.  Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. , 1997, Carcinogenesis.

[98]  Anna Saramäki,et al.  Cyclical Chromatin Looping and Transcription Factor Association on the Regulatory Regions of the p21 (CDKN1A) Gene in Response to 1α,25-Dihydroxyvitamin D3*S⃞ , 2009, Journal of Biological Chemistry.

[99]  D. Feldman,et al.  The role of vitamin D in prostate cancer , 2001, Steroids.

[100]  H. DeLuca,et al.  Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. , 2000, Archives of biochemistry and biophysics.

[101]  Paul Tempst,et al.  Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.

[102]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[103]  P. Malloy,et al.  Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. , 2004, Molecular endocrinology.

[104]  C. Allis,et al.  Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. , 1996, Current opinion in genetics & development.

[105]  C. Carlberg,et al.  Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. , 2005, Journal of molecular biology.

[106]  N. Pejnović,et al.  Disease modifying and immunomodulatory effects of high dose 1 ( OH ) D 3 in rheumatoid arthritis patients , 2006 .

[107]  M. Jäättelä,et al.  Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. , 1999, Cancer research.

[108]  H. Erdjument-Bromage,et al.  A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. , 1998, Genes & development.

[109]  C. Carlberg,et al.  All natural DR3-type vitamin D response elements show a similar functionality in vitro. , 2000, The Biochemical journal.

[110]  P. Cohen,et al.  Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. , 2001, The Journal of urology.

[111]  J. Hansen,et al.  Conformational dynamics of the chromatin fiber in solution: determinants, mechanisms, and functions. , 2002, Annual review of biophysics and biomolecular structure.

[112]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[113]  G. Gill,et al.  SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? , 2004, Genes & development.

[114]  E. Zimmermann,et al.  Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[115]  C. Carlberg,et al.  Natural vitamin D3 response elements formed by inverted palindromes: polarity-directed ligand sensitivity of vitamin D3 receptor-retinoid X receptor heterodimer-mediated transactivation , 1995, Molecular and cellular biology.

[116]  E. Froesch,et al.  Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. , 1989, Acta endocrinologica.

[117]  Martin Lipkin,et al.  The role of vitamin D in cancer prevention. , 2006, American journal of public health.

[118]  P. Shaw,et al.  Gene activation and deactivation related changes in the three-dimensional structure of chromatin , 2005, Chromosoma.

[119]  C. Carlberg,et al.  Gene regulatory potential of 1α,25‐dihydroxyvitamin D3 analogues with two side chains , 2001, Journal of cellular biochemistry. Supplement.

[120]  H. Koeffler,et al.  Characterization of a novel analogue of 1alpha,25(OH)(2)-vitamin D(3) with two side chains: interaction with its nuclear receptor and cellular actions. , 2000, Journal of medicinal chemistry.

[121]  S. Velasco-Miguel,et al.  Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.

[122]  A. Howie,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Extrarenal Expression of 25-Hydroxyvitamin , 2022 .